Overcoming barriers to effective blood pressure control in patients with hypertension

References

• Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. J Am Med Assoc 2003;289: 2363–9
   Google Scholar
• Cheung BM, Ong KL, Man YB, Lam KS, Lau CP. Prevalence, awareness, treatment, and control of hypertension: United States National Health and Nutrition Examination Survey 2001–2002. J Clin Hypertens (Greenwich) 2006;8: 93–8
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Hyper-tension among persons 20 years of age and over, according to sex, age, race, and Hispanic origin: United States, 1988–94 and 1999–2002 http://www.cdc.gov/nchs/data/hus/hus04trend.pdf#067 [accessed 20 April 2006]
   Google Scholar
• Kannel WB. Fifty years of Framingham Study contributions to understanding hypertension. J Hum Hypertens 2000;14: 83–90
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360: 1903–13
   Google Scholar
• Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001;103:1245–9
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Giles MF, Flossmann E, Lovelock CE, Redgrave JN, Warlow CP, et al. A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack. Lancet 2005;366:29–36
   PubMed Web of Science ®Google Scholar
• Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434–44
   PubMed Web of Science ®Google Scholar
• Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837–47
   PubMed Web of Science ®Google Scholar
• Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335: 827–38
   Google Scholar
• Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. J Am Med Assoc 2003;289:2534–44
   PubMed Web of Science ®Google Scholar
• Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003;21: 1055–76
   Google Scholar
• Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527–35
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206–52
   Google Scholar
• Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. J Am Med Assoc 2003;290:199–206
   PubMed Web of Science ®Google Scholar
• Mancia G, Parati G, Borghi C, Ghironzi G, Andriani E, Marinelli L, et al. Hypertension prevalence, awareness, control and association with metabolic abnormalities in the San Marino population: the SMOOTH study. J Hypertens 2006;24:837–43
   PubMed Web of Science ®Google Scholar
• Efstratopoulos AD, Voyaki SM, Baltas AA, Vratsistas FA, Kirlas DE, Kontoyannis JT, et al. Prevalence, awareness, treatment and control of hypertension in Hellas, Greece: the Hypertension Study in General Practice in Hellas (HYPERTENSHELL) national study. Am J Hypertens 2006;19:53–60
   PubMed Web of Science ®Google Scholar
• Brindel P, Hanon O, Dartigues JF, Ritchie K, Lacombe JM, Ducimetiere P, et al. Prevalence, awareness, treatment, and control of hypertension in the elderly: the Three City study. J Hypertens 2006;24:51–8
   PubMed Web of Science ®Google Scholar
• Ayala C, Neff LJ, Croft JB, Keenan NL, Malarcher AM, Hyduk A, et al. Prevalence of self-reported high blood pressure awareness, advice received from health professionals, and actions taken to reduce high blood pressure among US adults – healthstyles 2002. J Clin Hypertens (Greenwich ) 2005;7:513–9
   PubMedGoogle Scholar
• Maahs DM, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, Hokanson J, et al. Hypertension prevalence, awareness, treatment, and control in an adult type 1 diabetes population and a comparable general population. Diabetes Care 2005;28: 301–6
   Google Scholar
• Chua B, Rochtchina E, Mitchell P. Temporal changes in the control of blood pressure in an older Australian population. J Hum Hypertens 2005;19:691–6
   Google Scholar
• Laaser U, Breckenkamp J. Trends in risk factor control in Germany 1984–1998: high blood pressure and total cholesterol. Eur J Public Health 2006;16:217–22
   PubMed Web of Science ®Google Scholar
• Macedo ME, Lima MJ, Silva AO, Alcantara P, Ramalhinho V, Carmona J. Prevalence, awareness, treatment and control of hypertension in Portugal: the PAP study. J Hypertens 2005;23:1661–6
   PubMed Web of Science ®Google Scholar
• Agyemang C, Bruijnzeels MA, Owusu-Dabo E. Factors associated with hypertension awareness, treatment, and control in Ghana, West Africa. J Hum Hypertens 2006;20:67–71
   PubMed Web of Science ®Google Scholar
• Altun B, Arici M, Nergizoglu G, Derici U, Karatan O, Turgan C, et al. Prevalence, awareness, treatment and control of hyper-tension in Turkey (the PatenT study) in 2003. J Hypertens 2005;23:1817–23
   PubMed Web of Science ®Google Scholar
• Antikainen RL, Moltchanov VA, Chukwuma Sr C, Kuulasmaa KA, Marques-Vidal PM, Sans S, et al. Trends in the prevalence, awareness, treatment and control of hypertension: the WHO MONICA Project. Eur J Cardiovasc Prev Rehabil 2006; 13:13–29
   Google Scholar
• Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich ) 2002;4:393–404
   PubMedGoogle Scholar
• Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995–1003
   Google Scholar
• Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895–906
   PubMed Web of Science ®Google Scholar
• ESH/ESC Guidelines Committee. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011–53
   Google Scholar
• Agyemang C, Bindraban N, Mairuhu G, Montfrans G, Koopmans R, Stronks K. Prevalence, awareness, treatment, and control of hypertension among Black Surinamese, South Asian Surinamese and White Dutch in Amsterdam, The Netherlands: the SUNSET study. J Hypertens 2005;23:1971–7
   PubMed Web of Science ®Google Scholar
• Hertz RP, Unger AN, Cornell JA, Saunders E. Racial disparities in hypertension prevalence, awareness, and management. Arch Intern Med 2005;165:2098–104
   PubMed Web of Science ®Google Scholar
• Spranger CB, Ries AJ, Berge CA, Radford NB, Victor RG. Identifying gaps between guidelines and clinical practice in the evaluation and treatment of patients with hypertension. Am J Med 2004;117:14–8
   Google Scholar
• Cuspidi C, Michev I, Lonati L, Vaccarella A, Cristofari M, Garavelli G, et al. Compliance to hypertension guidelines in clinical practice: a multicentre pilot study in Italy. J Hum Hypertens 2002;16:699–703
   PubMed Web of Science ®Google Scholar
• Hobbs FD, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract 2002;19: 596–604
   PubMed Web of Science ®Google Scholar
• Kannel WB, Vasan RS. Assessment of cardiovascular risk and choice of antihypertensive therapy. Curr Hypertens Rep 2004;6:346–51
   PubMed Web of Science ®Google Scholar
• Williams B. Recent hypertension trials: implications and controversies. J Am Coll Cardiol 2005;45:813–27
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545–53
   Google Scholar
• Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trials. Hypertens Res 2005;28: 385–407
   PubMed Web of Science ®Google Scholar
• Papademetriou V, Farsang C, Elmfeldt D, Hofman A, Lithell H, Olofsson B, et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 2004;44:1175–80
   PubMed Web of Science ®Google Scholar
• Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36:1218–26
   PubMed Web of Science ®Google Scholar
• Dusing R, Lehnert H. Diabetogenic effect of antihypertensive treatment: primum nil nocere. Nephrol Dial Transplant 2004;19:531–4
   PubMed Web of Science ®Google Scholar
• Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006;24:3–10
   PubMed Web of Science ®Google Scholar
• ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc 2002;288:2981–97
   Google Scholar
• Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002;20:1461–4
   PubMed Web of Science ®Google Scholar
• Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. J Am Med Assoc 2003;289:2073–82
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial [HOT Study Group]. Lancet 1998;351:1755–62
   PubMed Web of Science ®Google Scholar
• Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo [The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents]. New Engl J Med 1993;328:914–21
   Google Scholar
• Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. Can Med Assoc J 1999;160:41–6
   Google Scholar
• Moser M. Rationale for combination therapy in the management of hypertension. J Clin Hypertens (Greenwich ) 2003;5:17–25
   PubMedGoogle Scholar
• Dusing R, Weisser B, Mengden T, Vetter H. Changes in antihypertensive therapy – the role of adverse effects and compliance. Blood Press 1998;7:313–5
   PubMedGoogle Scholar
• Institute for Clinical Systems Improvement (ICSI). Hypertension diagnosis and treatment. Bloomington (MN): ICSI; 2005. p. 53
   Google Scholar
• Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. New Engl J Med 2000;343:16–22
   Google Scholar
• Department of Health and Human Services. Physical activity and health: a report of the Surgeon General. Atlanta: National Center for Chronic Disease Prevention and Health Promotion. 1996; http://www.cdc.gov/nccdphp/sgr/sgr.htm [accessed 31 May 2006]
   Google Scholar
• Korhonen MH, Litmanen H, Rauramaa R, Vaisanen SB, Niskanen L, Uusitupa M. Adherence to the salt restriction diet among people with mildly elevated blood pressure. Eur J Clin Nutr 1999;53:880–5
   PubMed Web of Science ®Google Scholar
• Appel LJ, Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. J Am Med Assoc 2003;289:2083–93
   PubMed Web of Science ®Google Scholar
• Elliott WJ. Optimizing medication adherence in older persons with hypertension. Int Urol Nephrol 2003;35:557–62
   PubMedGoogle Scholar
• Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med 2004;164:722–32
   Google Scholar
• Krousel-Wood M, Thomas S, Muntner P, Morisky D. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol 2004;19:357–62
   Google Scholar
• Neutel JM, Smith DH. Improving patient compliance: a major goal in the management of hypertension. J Clin Hypertens (Greenwich) 2003;5:127–32
   PubMedGoogle Scholar
• Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J. The effects of initial drug choice and comorbidity on anti-hypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens 1997;10:697–704
   PubMed Web of Science ®Google Scholar
• Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther 2001;23:1999–2010
   Google Scholar
• Thaker D, Frech F, Gause D, Zhang W. Patient compliance and persistency with antihypertensive agents: a comparison of agents in different therapeutic classes. Am J Hypertens 2005;18:A222
   Google Scholar
• Mancia G, Seravalle G, Grassi G. Tolerability and treatment compliance with angiotensin II receptor antagonists. Am J Hypertens 2003;16:1066–73
   Google Scholar